Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Science of Handcycling: A Narrative Review.
Nevin J, Kouwijzer I, Stone B, Quittmann OJ, Hettinga F, Abel T, Smith PM. Nevin J, et al. Int J Sports Physiol Perform. 2022 Mar 1;17(3):335-342. doi: 10.1123/ijspp.2021-0458. Epub 2022 Feb 7. Int J Sports Physiol Perform. 2022. PMID: 35130511 Free article. Review.
Efficacy of an 8-Week Concurrent Strength and Endurance Training program on Hand Cycling Performance.
Nevin J, Smith P, Waldron M, Patterson S, Price M, Hunt A, Blagrove R. Nevin J, et al. J Strength Cond Res. 2018 Jul;32(7):1861-1868. doi: 10.1519/JSC.0000000000002569. J Strength Cond Res. 2018. PMID: 29561384
Nevin, JP, Smith, P, Waldron, M, Patterson, S, Price, M, Hunt, A, and Blagrove, R. Efficacy of an 8-week concurrent strength and endurance training program on hand cycling performance. J Strength Cond Res 32(7): 1861-1868, 2018-The aim of this study was to investiga …
Nevin, JP, Smith, P, Waldron, M, Patterson, S, Price, M, Hunt, A, and Blagrove, R. Efficacy of an 8-week concurrent strength and endu …
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B, Kishnani PS, Bratkovic D, Byrne BJ, Claeys KG, Díaz-Manera J, Laforêt P, Roberts M, Toscano A, van der Ploeg AT, Castelli J, Goldman M, Holdbrook F, Sitaraman Das S, Wasfi Y, Mozaffar T; ATB200-07 Study Group. Schoser B, et al. J Neurol. 2024 May;271(5):2810-2823. doi: 10.1007/s00415-024-12236-0. Epub 2024 Feb 28. J Neurol. 2024. PMID: 38418563 Free PMC article. Clinical Trial.
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease.
Liyanage G, Trewin BP, Lopez JA, Andersen J, Tea F, Merheb V, Nguyen K, Lee FXZ, Fabis-Pedrini MJ, Zou A, Buckland A, Fok A, Barnett MH, Reddel SW, Marignier R, El Hajj A, Monif M, van der Walt A, Lechner-Scott J, Kermode AG, Kalincik T, Broadley SA, Dale RC, Ramanathan S, Brilot F; on behalf the Australasian MOGAD Study Group. Liyanage G, et al. J Neurol Neurosurg Psychiatry. 2024 May 14;95(6):544-553. doi: 10.1136/jnnp-2023-332851. J Neurol Neurosurg Psychiatry. 2024. PMID: 38290838 Free PMC article.
Generic versus disease-specific adverse event reporting: a comparison of the NSQIP and SAVES databases for the identification of acute care adverse events in adult spine surgery.
Moskven E, Daly CD, Nevin J, Bourassa-Moreau É, Ailon T, Charest-Morin R, Dea N, Dvorak MF, Fisher CG, Kwon BK, Paquette S, Street JT. Moskven E, et al. Among authors: nevin j. J Neurosurg Spine. 2023 Apr 28;39(2):263-270. doi: 10.3171/2023.3.SPINE221437. Print 2023 Aug 1. J Neurosurg Spine. 2023. PMID: 37119107
240 results